|
|
|
|
|
Click Here to return To Results
|
|
|
|
Time to withdrawal for lack of efficacy or adverse events did not differ between groups (p=0.318). Vigabatrin was better tolerated than carbamazepine with fewer withdrawals, but was more frequently associated with psychiatric symptoms (58 [ 25%] vs 34 [15%]) and weight gain (25 [11%] vs 12 [5%]). Carbamazepine was associated with rash (22 [10%] vs seven [3%}). All efficacy outcomes favoured carbamazepine and failed to show equivalence between the two drugs. No significant difference was f ound for time to achieve 6 months of remission from seizures (p=0.058), but the most powerful outcome, time to first seizure after the first 6 weeks from randomisation, showed carbamazepine to be significantly more effective than vigabatrin (p=0.0001). Vigabatrin seems less effective but better tolerated than carbamazepine, which is first-choice drug for the treatment of partial epilepsies. Vigabatrin cannot therefore be recommended as a first-line drug for monotherapy in this group of patients. |
|
(click to filter results - removes previous filter)
adverse drug reaction
anticonvulsants,effectiveness
anticonvulsants,untoward effects of
carbamazepine
seizure
seizure,treatment of
seizure,treatment of,monotherapy
treatment of neurologic disorder
vigabatrin
|
Click Here to return To Results
|
|